-
21.发明公开돌외의 지페노사이드 추출물을 포함하는 제2형 당뇨병, 비만 또는 고지혈증의 치료 또는 예방용 조성물 审中-实审用于治疗或预防包含GYNOSTEMMA PENTAPHLLLUM的GYPENOSIDE提取物的II型糖尿病，肥胖症或高脂血症的组合物
公开(公告)号：KR1020140108621A
公开(公告)日：2014-09-12
申请号：KR1020140097045
申请日：2014-07-30
Applicant: (주)셀트리온
IPC: A61K31/704 , A61K31/56 , A61K36/424 , A61P3/04 , A61P3/06
CPC classification number: A61K31/704 , A23L33/105 , A61K36/424 , A61K2236/333 , A61P3/04 , A61P3/06 , C07J17/005 , C07J19/005 , Y10S514/866 , Y10S514/909
Abstract: The present invention relates to a pharmaceutical composition or a functional health food comprising a gypenoside extract of gynostemma pentaphyllum, as an active ingredient, which contains at least one dammarane-based triterpenoid saponin compounds selected from the group consisting of gypenoside UL1, gypenoside UL2, gypenoside UL3, gypenoside UL4, gypenoside UL5, gypenoside UL6, gypenoside Ul7, and gypenoside XLVIII for treating or preventing obesity, type II diabetes, or hyperlipidemia.
Abstract translation: 本发明涉及一种药物组合物或功能性保健食品，其包含绞股蓝绞质的绞股蓝提取物作为活性成分，其含有至少一种选自甲硝甙类UL1，格硝酸苷UL2，木糖苷 UL3，gypenoside UL4，gypenoside UL5，gypenoside UL6，gypenoside Ul7和gypenoside XLVIII，用于治疗或预防肥胖，II型糖尿病或高脂血症。
-
Patent Agency Ranking
公开(公告)号：KR1020140038324A
公开(公告)日：2014-03-28
申请号：KR1020130111137
申请日：2013-09-16
Applicant: (주)셀트리온
IPC: C07D207/12 , A61K31/4015 , A61P35/00
CPC classification number: C07K7/06 , A61K31/40 , A61K31/421 , A61K31/426 , A61K38/00 , C07D207/12 , C07D401/12 , C07D409/12 , C07K5/0205 , C07K5/06052
Abstract: The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method for manufacturing the same, and an anticancer drug composition comprising the same as an active ingredient. The dolastatin-10 derivative of the present invention is a novel synthetic compound which can be used for treating a tumor, slowing growth of tumors, and preventing an increase in number of tumors. For example, the dolastatin-10 derivative is effective to inhibit or prevent the growth of tumor in permalignant and malignant cells.
Abstract translation: 本发明提供具有优异的抗癌活性的多拉司他汀-10衍生物，其制造方法和包含该组合物作为活性成分的抗癌药物组合物。 本发明的多拉司他汀-10衍生物是可用于治疗肿瘤，减缓肿瘤生长和防止肿瘤数量增加的新型合成化合物。 例如，多拉司他汀-10衍生物可有效抑制或阻止去角质和恶性细胞中肿瘤的生长。
-
公开(公告)号：KR101898441B1
公开(公告)日：2018-09-13
申请号：KR1020180035919
申请日：2018-03-28
Applicant: (주)셀트리온
Abstract: 본발명은에피제네틱조절기능을갖는펩타이드를포함하는화장료조성물및 약학적조성물에관한것으로, 보다상세하게본 발명은피부주름개선또는피부탄력증진용펩타이드를포함하는화장료조성물및 약학적조성물에관한것이다. 본발명의펩타이드를포함하는화장료조성물및 약학적조성물은 MMP-1 유전자발현을억제하여, 피부주름개선및 피부탄력증진에우수한효과가있다.
-
公开(公告)号：KR1020170133845A
公开(公告)日：2017-12-06
申请号：KR1020160065148
申请日：2016-05-26
Applicant: (주)셀트리온
IPC: A61K8/67 , A61K8/64 , A61K8/49 , A61K8/55 , A61K31/375 , A61K31/34 , A61K31/66 , A23L33/15 , A23L1/305
Abstract: 본발명은펩타이드가결합된안정한아스코르빈산유도체를포함하는피부염증완화용조성물에관한것으로, 본발명의펩타이드가결합된아스코르빈산유도체는 NO 및 PGE2 생성을억제하므로피부염증완화에우수한효과가있다.
Abstract translation: 本发明涉及一种用于皮肤炎症，其包括稳定的抗坏血酸衍生物的组合物的肽键合，因为本发明的抗坏血酸衍生物的肽结合的抑制NO和PGE2产生的皮肤或炎症的优异效果 有。
-
公开(公告)号：KR101652204B1
公开(公告)日：2016-08-29
申请号：KR1020150147473
申请日：2015-10-22
Applicant: (주)셀트리온
IPC: C07D307/62 , A61K8/67 , A61K8/64 , A61Q19/00 , A61Q19/02
CPC classification number: C07F9/65846 , A61K8/00 , A61K8/676 , A61K9/0014 , A61K9/06 , A61K47/14 , A61K47/42 , A61K47/48 , A61K47/48246 , A61K51/08 , A61Q19/00 , A61Q19/02 , A61Q19/08 , C07D307/62 , C07F9/65515 , C07H11/04 , C07K5/00
Abstract: 본발명은펩타이드가결합된안정한아스코르빈산유도체, 그의제조방법및 그를유효성분으로포함하는화장료조성물을제공한다. 본발명의펩타이드가결합된아스코르빈산유도체는멜라닌생성억제를통한미백효과및 콜라겐생성활성화를통한주름개선효과를동시에나타내는이중복합기능을가지며, 화장료조성물에사용될수 있다.
-
公开(公告)号：KR101597101B1
公开(公告)日：2016-02-25
申请号：KR1020140000819
申请日：2014-01-03
Applicant: (주)셀트리온
Inventor： 박영준 , 정진교 , 최영미 , 이민섭 , 최준헌 , 이진서 , 조은주 , 송현남 , 박성준 , 이종협 , 이상엽 , 이인숙 , 김준우 , 홍승서 , 김연정 , 김경석
IPC: C07D403/12 , A61K31/4025 , A61K39/395 , A61K47/48 , A61P35/00
Abstract: 본발명은항체의라이신잔기에직접결합할수 있는효소-분해형펩타이드링커를통해항체와세포독성약물이접합된항체-링커-약물결합체, 그의제조방법및 그를유효성분으로포함하는항암제조성물을제공한다.
-
-
-
-
-
Search Results
26
records
(took 0.032 seconds)
